These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 17851225

  • 1. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer.
    Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN, Yu QZ.
    Respiration; 2008; 75(4):380-5. PubMed ID: 17851225
    [Abstract] [Full Text] [Related]

  • 2. MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer.
    Sohn JW, Lee SY, Lee SJ, Kim EJ, Cha SI, Kim CH, Lee JT, Jung TH, Park JY.
    Jpn J Clin Oncol; 2006 Mar; 36(3):137-41. PubMed ID: 16478794
    [Abstract] [Full Text] [Related]

  • 3. MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer.
    Pan JH, Han JX, Wu JM, Huang HN, Yu QZ, Sheng LJ.
    Respiration; 2009 Mar; 78(1):49-55. PubMed ID: 18812689
    [Abstract] [Full Text] [Related]

  • 4. CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer.
    Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN.
    Acta Oncol; 2007 Mar; 46(3):361-6. PubMed ID: 17450472
    [Abstract] [Full Text] [Related]

  • 5. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients.
    Chen S, Huo X, Lin Y, Ban H, Lin Y, Li W, Zhang B, Au WW, Xu X.
    Int J Hyg Environ Health; 2010 Mar; 213(2):140-5. PubMed ID: 20189873
    [Abstract] [Full Text] [Related]

  • 6. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine.
    Viñolas N, Provencio M, Reguart N, Cardenal F, Alberola V, Sánchez-Torres JM, Barón FJ, Cobo M, Maestu I, Moreno I, Mesía C, Izquierdo A, Felip E, López-Brea M, Márquez A, Sánchez-Ronco M, Tarón M, Santarpia MC, Rosell R, Spanish Lung Cancer Group.
    Lung Cancer; 2011 Feb; 71(2):191-8. PubMed ID: 20627363
    [Abstract] [Full Text] [Related]

  • 7. XPC gene intron 11 C/A polymorphism is a predictive biomarker for the sensitivity to NP chemotherapy in patients with non-small cell lung cancer.
    Zhu LB, Xu Q, Hong CY, Yue Z, Zhang Y, Ye HN, Yuan Y.
    Anticancer Drugs; 2010 Aug; 21(7):669-73. PubMed ID: 20571354
    [Abstract] [Full Text] [Related]

  • 8. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.
    Gautschi O, Hugli B, Ziegler A, Bigosch C, Bowers NL, Ratschiller D, Jermann M, Stahel RA, Heighway J, Betticher DC.
    Lung Cancer; 2006 Mar; 51(3):303-11. PubMed ID: 16406195
    [Abstract] [Full Text] [Related]

  • 9. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, Lu C, Zuhong L, Hongyan C, YuanDong C, Jiazhong J, Yingfeng Z.
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [Abstract] [Full Text] [Related]

  • 10. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
    Yuan P, Miao XP, Zhang XM, Wang ZH, Tan W, Sun Y, Xu BH, Lin DX.
    Zhonghua Yi Xue Za Zhi; 2005 Apr 13; 85(14):972-5. PubMed ID: 16061005
    [Abstract] [Full Text] [Related]

  • 11. A phase II randomized study of vinorelbine alone or with cisplatin against chemo-naïve inoperable non-small cell lung cancer in the elderly.
    Chen YM, Perng RP, Shih JF, Whang-Peng J.
    Lung Cancer; 2008 Aug 13; 61(2):214-9. PubMed ID: 18243407
    [Abstract] [Full Text] [Related]

  • 12. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.
    Wong M, Balleine RL, Blair EY, McLachlan AJ, Ackland SP, Garg MB, Evans S, Farlow D, Collins M, Rivory LP, Hoskins JM, Mann GJ, Clarke CL, Gurney H.
    J Clin Oncol; 2006 Jun 01; 24(16):2448-55. PubMed ID: 16651648
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer.
    Bi N, Yang M, Zhang L, Chen X, Ji W, Ou G, Lin D, Wang L.
    Clin Cancer Res; 2010 Apr 15; 16(8):2383-90. PubMed ID: 20332326
    [Abstract] [Full Text] [Related]

  • 15. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene.
    Johne A, Köpke K, Gerloff T, Mai I, Rietbrock S, Meisel C, Hoffmeyer S, Kerb R, Fromm MF, Brinkmann U, Eichelbaum M, Brockmöller J, Cascorbi I, Roots I.
    Clin Pharmacol Ther; 2002 Nov 15; 72(5):584-94. PubMed ID: 12426522
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.
    Mir O, Alexandre J, Ropert S, Montheil V, Martin I, Durand JP, Goldwasser F.
    Anticancer Drugs; 2009 Feb 15; 20(2):105-8. PubMed ID: 19209026
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
    Reck M, Macha HN, Del Barco S, Cornes P, Vaissière N, Morand M, Riggi M, Abratt R.
    Lung Cancer; 2009 Jun 15; 64(3):319-25. PubMed ID: 19095327
    [Abstract] [Full Text] [Related]

  • 20. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer.
    Booton R, Ward T, Heighway J, Taylor P, Power F, Ashcroft L, Morris J, Thatcher N.
    Cancer; 2006 Jun 01; 106(11):2421-7. PubMed ID: 16649224
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.